New research suggests that people who stop using new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight far faster than those who end conventional lifestyle programs.
Research printed in a major medical journal demonstrates that while obese people often shed about a fifth of their body weight while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month after stopping.
"Individuals buying these medications need to be cognizant of the risk of fast rebound weight gain when the medication concludes," stated lead investigator Dr. Susan Jebb.
That rate of recovery means a return to pre-treatment mass in about one and a half years.
Comparing Approaches
The research, which looked at dozens of studies involving over 9,000 of participants, contrasted the effects of these new drugs with older methods.
The team note that individuals who shed pounds through diet and exercise typically have a more gradual creep back—perhaps 0.1 kg a month—after stopping.
Understanding the Rapid Regain
Nutrition scientists believe the way of the drugs is key to understanding the amplified regain.
These medications copy a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing GLP-1 concentrations far above than the body's typical production may cause the body to generate a reduced amount of its own natural hormone, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' means hunger is unsuppressed, making excessive eating far more likely."
A Chronic Issue?
The NHS recommend the injections for people with obesity-related health risks, alongside prescribed lifestyle changes.
A number of clinicians say that, given the high risk of relapse, the therapy is often long-term.
This perspective is echoed by pharmaceutical companies, who state that the results "underscore the long-term nature of obesity," similar to managing diseases like hypertension.
Patient Testimonies
People who have discontinued the jabs describe a intense return of hunger.
"I experienced something activating and I was suddenly extremely hungry," said a patient.
This challenge is compounded if individuals have not developed permanent dietary or behavioural changes during treatment.
Widespread Use
Recent estimates suggest that a significant number of adults in the UK have tried these injections in the past year, with interest being substantial.
- Use is greater among women than men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
In conclusion, clinicians caution that while GLP-1 drugs are effective agents for shedding pounds, they are not a magic solution and long-term success hinges on ongoing behavioural changes.
